{"disease":{"id":"antibody","name":"antibody"},"drugs":{"marketed":[{"drug_id":"avacopan","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"AVACOPAN","company_name":"Chemocentryx","drug_phase":"marketed","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist [EPC]","quality_score":62,"revenue":"400","mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response."},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"ccx168","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"CCX168","company_name":"Chemocentryx","drug_phase":"discontinued","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist","quality_score":null,"revenue":null,"mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels."}],"pipeline":[],"offLabel":[],"totalMarketed":20,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05084950","title":"Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Centre Scientifique de Monaco","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03408158","title":"HPA Antibodies and the Distribution of Antigen and Antibodies","phase":"NA","overall_status":"COMPLETED","enrollment_count":6170,"lead_sponsor_name":"Guangzhou First People's Hospital","has_results":false},{"nct_id":"NCT06021925","title":"Obstetrical History and Anti-HLA Antibodies Level","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05219097","title":"The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":2663,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT04591470","title":"Influence of Inguinal Hernia Repair on Sperm Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":2415,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT05545371","title":"Prevention of Rabies With Four Doses of Rabies Vaccine","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2100,"lead_sponsor_name":"Changchun Zhuoyi Biological Co., Ltd","has_results":false},{"nct_id":"NCT05549908","title":"Vaccine Prevention of Rabies Adopts 4-shot Immunization Method","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Changchun Zhuoyi Biological Co., Ltd","has_results":false},{"nct_id":"NCT07333196","title":"Tongji NADs Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03900221","title":"French Registry for Monitoring Pregnancies for Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06168032","title":"COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","phase":"NA","overall_status":"RECRUITING","enrollment_count":1224,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05076227","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","phase":"","overall_status":"COMPLETED","enrollment_count":1206,"lead_sponsor_name":"Serge Thal","has_results":false},{"nct_id":"NCT05124535","title":"Population-based Age-stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection in the Federation of Bosnia and Herzegovina","phase":"","overall_status":"UNKNOWN","enrollment_count":1152,"lead_sponsor_name":"Institute for Public Health of the Federation of Bosnia and Herzegovina","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT05904301","title":"Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Santé Arménie French-Armenian Research Center","has_results":false},{"nct_id":"NCT07202494","title":"Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT06921460","title":"Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":624,"lead_sponsor_name":"PT Bio Farma","has_results":false},{"nct_id":"NCT04627012","title":"Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04459312","title":"National Covid-19 Surveillance Physicians","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT03393793","title":"HEart trAnsplantation Registry of piTie-Salpetriere University Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":566,"lead_sponsor_name":"Lee S Nguyen","has_results":false},{"nct_id":"NCT06532006","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04319341","title":"Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia","phase":"","overall_status":"COMPLETED","enrollment_count":513,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT05017142","title":"Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Bern","has_results":false},{"nct_id":"NCT03766932","title":"Antigenic and Antibody Detection of Candida","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07316465","title":"Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT03613636","title":"Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)","phase":"","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"University Children's Hospital, Zurich","has_results":false},{"nct_id":"NCT06541626","title":"Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03719339","title":"VIRTUUS Children's Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT03814837","title":"A Study for the Ocular Toxocariasis Patients With the Pulmonary Toxocariasis, and Ocular Toxocariasis Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"University of Ulsan","has_results":false},{"nct_id":"NCT06917560","title":"Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT03668496","title":"A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":390,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01520272","title":"HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda","phase":"","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05953974","title":"Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05197673","title":"Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures","phase":"NA","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06072482","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04368962","title":"DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT07126652","title":"Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05465265","title":"PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06308978","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT07374484","title":"Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06323382","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06617962","title":"Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT05140018","title":"Incidence, Course and Outcome of ABMR in Kidney Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":225,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT07309497","title":"Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT05969522","title":"Stratified Therapy on Pediatric AAGN","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Wang Mo","has_results":false},{"nct_id":"NCT05605951","title":"Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul","has_results":false},{"nct_id":"NCT03815864","title":"Antibodies and Liver Retransplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"London Health Sciences Centre","has_results":false},{"nct_id":"NCT05004493","title":"Biorepository and Registry for Plasma Exchange Patients","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Charles M Knudson","has_results":false},{"nct_id":"NCT04514081","title":"The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07133113","title":"Medium-term Effects of Treatments in Autoimmune Encephalitis","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}